CCTV Beijing, April 22 (Reporter Yu Qi) A few days ago, Lepu (Beijing) Medical Devices Co., Ltd. (hereinafter referred to as "Lepu Medical") released its 2023 annual report and 2024 first quarter report.
According to financial data, in 2023, Lepu Medical will achieve revenue of 7.98 billion yuan, down 24.78% year-on-year, net profit attributable to shareholders of listed companies of 1.258 billion yuan, down 42.91% year-on-year, basic earnings per share of 0.68 yuan, and cash dividend of 3.31 yuan (tax included) for every 10 shares to all shareholders.
(Screenshot from Lepu Medical's 2023 annual report)
It is worth noting that in 2023, Lepu Medical's net profit level will hit a new low in recent years. According to the 2023 annual report, from 2021 to 2022, the company's revenue will be 10.66 billion yuan and 10.61 billion yuan respectively, and the net profit attributable to shareholders of listed companies will be 1.719 billion yuan and 2.204 billion yuan respectively. In addition, according to the 2021 annual report, from 2019 to 2020, Lepu Medical's net profit attributable to shareholders of listed companies was 1.725 billion yuan and 1.802 billion yuan respectively.
(Screenshot from Lepu Medical's 2021 annual report)
Lepu Medical said that the main reason for the decline in the company's operating income and net cash flow from operating activities in 2023 is that the emergency rapid test kit and PCR instruments and equipment in the same period last year contributed significantly to the revenue and net cash flow from operating activities in the same period.
In terms of quarters, from the first quarter of 2023 to the third quarter, the net profit attributable to shareholders of listed companies was 597 million yuan, 365 million yuan and 392 million yuan respectively, and in the fourth quarter of 2023, Lepu Medical achieved operating income of 1.721 billion yuan, net profit attributable to shareholders of listed companies -95.4005 million yuan, and net profit after deducting non-profits of -163 million yuan, turning from profit to loss year-on-year.
(Screenshot from Lepu Medical's 2023 annual report)
In the first quarter of 2024, Lepu Medical's revenue and net profit continued to decline, achieving revenue of 1.922 billion yuan, down 21.14% year-on-year, net profit attributable to shareholders of listed companies of 482 million yuan, down 19.27% year-on-year, and corresponding net profit after deducting non-profits of 456 million yuan, down 18.85% year-on-year. Lepu Medical explained in the financial report that the main reason for the year-on-year decline in revenue in the first quarter was that there were still some emergency product sales last year, and they were concentrated in the first quarter, and the decrease in net profit was mainly due to the decrease in government subsidies.
(Screenshot from Lepu Medical's 2023 annual report)
According to public information, Lepu Medical, founded in 1991, is a provider of overall solutions for the whole life cycle in the field of cardiovascular diseases, and the company's business segments are divided into medical devices, drugs, medical services and health management. In October 2009, the company was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange.
At the secondary market level, as of the close of trading on April 22, Lepu Medical reported 13.90 yuan per share, and the company's total market value was 26.14 billion yuan.
（截图自同花顺iFinD）
For more exciting information, please download the "Central Radio Network" client in the application market. Welcome to provide news clues, 24-hour reporting hotline 400-800-0088, consumers can also complain online through the "Woodpecker Consumer Complaint Platform" of CCTV. Copyright Notice: The copyright of this article belongs to CCTV, and it may not be reproduced without authorization. Please contact [email protected] for reprinting, we will be held accountable for not respecting the original.